NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) issued a draft guidance on Friday stating that it does not recommend abemaciclib (Eli Lily's Verzenio) for patients with hormone receptor-positive, HER2-negative, advanced breast cancer.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.